14:52 , Jun 29, 2018 |  BC Week In Review  |  Financial News

AbbVie Ventures, HealthCap lead Carisma's $53M series A

Macrophage immunotherapy company Carisma Therapeutics Inc. (Philadelphia, Pa.) raised $53 million in a series A round led by existing investors AbbVie Ventures and HealthCap. Existing investors IP Group plc (LSE:IPO), Penn Medicine and Grazia Equity,...
04:01 , Jun 27, 2018 |  BC Extra  |  Financial News

AbbVie Ventures, HealthCap lead Carisma's $53M series A

Macrophage immunotherapy company Carisma Therapeutics Inc. (Philadelphia, Pa.) raised $53 million in a series A round led by existing investors AbbVie Ventures and HealthCap. Existing investors IP Group plc (LSE:IPO), Penn Medicine and Grazia Equity,...
19:51 , Oct 13, 2017 |  BC Week In Review  |  Financial News

Allena proposes $92M IPO

Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million on Oct. 6 in an IPO on NASDAQ underwritten by Credit Suisse, Jefferies, Wedbush and Cowen. Allena's lead candidate, ALLN-177...
19:53 , Oct 9, 2017 |  BC Extra  |  Financial News

Allena proposes $92M IPO

Kidney disease company Allena Pharmaceuticals Inc. (Newton, Mass.) proposed to raise up to $92 million in an IPO on NASDAQ underwritten by Credit Suisse, Jefferies, Wedbush and Cowen. Allena's lead candidate, ALLN-177 , is an...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Company News

Ajinomoto management update

Ajinomoto Co. Inc. (Tokyo:2802), Tokyo, Japan   Business: Gastrointestinal, Endocrine/Metabolic, Nutraceuticals   Hired: J. David Enloe as president and CEO of Ajinomoto's Ajinomoto Althea Inc. subsidiary, formerly head of the viral therapeutics business unit at...
08:00 , Dec 19, 2013 |  BC Innovations  |  Cover Story

Oral nanoparticles

Researchers from Brigham and Women's Hospital and the Massachusetts Institute of Technology have developed targeted nanoparticles that could enable the oral delivery of biologics such as insulin. 1 The clinical translation of the approach will...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Financial News

Telegraph Hill Partners financial update

Telegraph Hill Partners closed its third fund with $310 million. The firm, which focuses on diagnostics, medical devices, healthcare IT and life science tools, said it will invest the fund in 10-12 high-growth, commercial-stage companies...
00:41 , Aug 2, 2013 |  BC Extra  |  Financial News

Telegraph Hill raises $310M for third fund

Telegraph Hill Partners closed its third fund with $310 million. The firm, which focuses on diagnostics, medical devices, healthcare IT and life science tools, said it will invest the fund in 10-12 high-growth, commercial-stage companies...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Ajinomoto, Althea deal

Ajinomoto completed the acquisition of development and manufacturing services company Althea for about $175 million. Althea will become a fully owned subsidiary of Ajinomoto and will operate under the name Ajinomoto Althea Inc. (see BioCentury,...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Company News

Ajinomoto, Althea deal

Ajinomoto will acquire development and manufacturing services Althea for about $175 million. The deal is expected to close in early April. Althea, which has revenues of about $53 million, will become a fully owned subsidiary...